Eculizumab therapy for atypical haemolytic uraemic syndrome due to a gain-of-function mutation of complement factor B

[1] Loirat C(2011)Atypical hemolytic uremic syndrome Orphanet J Rare Dis 6 60-E1460

[2] Frémeaux-Bacchi V(2010)Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome Hum Mutat 31 E1445-2379

[3] Maga TK(2008)The tick-over theory revisited: formation and regulation of the soluble alternative complement C3 convertase (C3(H2O)Bb) Mol Immunol 45 2370-230

[4] Nishimura CJ(1988)Complement evasion by bacteria and parasites Annu Rev Microbiol 42 201-1066

[5] Weaver AE(2012)Manipulating the mediator: modulation of the alternative complement pathway C3 convertase in health, disease and therapy Immunobiology 217 1057-245

[6] Frees KL(2007)Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome Proc Natl Acad Sci USA 104 240-158

[7] Smith RJH(2013)Neonatal onset hemolytic uremic syndrome successfully treated with eculizumab Pediatr Nephrol 28 155-2331

[8] Bexborn F(2012)Eculizumab therapy in a child with hemolytic uremic syndrome and CFI mutation Pediatr Nephrol 27 2327-619

[9] Andersson PO(2011)Eculizumab induces long-term remission in recurrent post transplant HUS associated with C3 gene mutation Pediatr Nephrol 26 613-4355

[10] Chen H(2010)Eculizumab: safety and efficacy after 17 months of treatment in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome: case report Transplant Proc 42 4353-558

[1] Loirat C(2011)Atypical hemolytic uremic syndrome Orphanet J Rare Dis 6 60-E1460

[2] Frémeaux-Bacchi V(2010)Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome Hum Mutat 31 E1445-2379

[3] Maga TK(2008)The tick-over theory revisited: formation and regulation of the soluble alternative complement C3 convertase (C3(H2O)Bb) Mol Immunol 45 2370-230

[4] Nishimura CJ(1988)Complement evasion by bacteria and parasites Annu Rev Microbiol 42 201-1066

[5] Weaver AE(2012)Manipulating the mediator: modulation of the alternative complement pathway C3 convertase in health, disease and therapy Immunobiology 217 1057-245

[6] Frees KL(2007)Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome Proc Natl Acad Sci USA 104 240-158

[7] Smith RJH(2013)Neonatal onset hemolytic uremic syndrome successfully treated with eculizumab Pediatr Nephrol 28 155-2331

[8] Bexborn F(2012)Eculizumab therapy in a child with hemolytic uremic syndrome and CFI mutation Pediatr Nephrol 27 2327-619

[9] Andersson PO(2011)Eculizumab induces long-term remission in recurrent post transplant HUS associated with C3 gene mutation Pediatr Nephrol 26 613-4355

[10] Chen H(2010)Eculizumab: safety and efficacy after 17 months of treatment in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome: case report Transplant Proc 42 4353-558